Identification of Predictive Gene Expression Profile of Sunitinib Response in Metastatic Clear Cell Renal Carcinomas

Exclusion Criteria

• •insufficient sample for molecular analysis
• •Patients with no record of treatment response data
• •Patients with a history of previous systemic treatment for Metastatic clear cell renal carcinoma
• •Patients with second primary synchronic or metachronic tumor undergoing treatment
• •Patients having received less than one cycle of sunitinib in the first line
• •Patients have received previous adjuvant and/or neoadjuvant treatment with an interval \< 1 year between the end of treatment and the diagnosis of metastasis.